Pfizer stock bounded off its 50-day line on Monday after avoiding a battle with activist investor Starboard Value — for ...

Radiotherapy, China's biotech surge and AI's role in drug discovery are notable topics that emerged from conversations on the ...

This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...

What does Trump's decision to leave the WHO mean for public health? And should U.S. companies be intimidated by Chinese drug ...

A major conference that took place earlier this month is set to return to San Francisco next year, according to SF Mayor Daniel Lurie’s office. The J.P. Morgan ...

What are biopharma VCs looking to invest in this year? Autoimmune disorders, osteoporosis, and cardiovascular disease are ...

Cautious Optimism for Deal Making. The general consensus is that we will likely see an increase in M&A and capital market transactions in the ...

Health care executives continue to reimagine and reshape their organizations. Their ideas were developing in real time during ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

Healthcare leaders shared insights on various topics, including industry challenges, a new administration and growing their ...